Former Ark CEO's start-up launches with Merck deal
September 20, 2011 at 03:52 AM EDT
LONDON, Sept 20 (Reuters) - A start-up led by Nigel Parker, the former chief executive of Ark Therapeutics , has secured a contract to develop Merck & Co's gene therapy portfolio, including a candidate to treat bladder cancer.
